iPS研究先驅(qū)日本京都大學(xué)教授山中伸彌教授帶領(lǐng)團(tuán)隊在新一期《自然·生物技術(shù)》雜志上報告說，動物實驗證明,，用不同種類的體細(xì)胞培育出的誘導(dǎo)多能干細(xì)胞（iPS）移植后使實驗鼠出現(xiàn)腫瘤的危險性存在很大差異,。
研究人員分別利用小鼠胚胎的皮膚細(xì)胞、成年小鼠的胃細(xì)胞,、尾巴的皮膚細(xì)胞以及肝臟細(xì)胞培育iPS細(xì)胞,。利用不同的體細(xì)胞和培育方法，研究人員共培育出36種iPS細(xì)胞,。
接著,，他們又使這36種iPS細(xì)胞都分化成具備演變成神經(jīng)能力的細(xì)胞，并把這些細(xì)胞植入另一些實驗鼠的大腦,。結(jié)果顯示,，被植入分化細(xì)胞來自成年小鼠尾巴皮膚細(xì)胞的實驗鼠中有83％體內(nèi)出現(xiàn)了腫瘤；被植入分化細(xì)胞來自于小鼠胚胎皮膚細(xì)胞的實驗鼠中只有8％出現(xiàn)腫瘤,；而如果實驗鼠移植的分化細(xì)胞來自成年小鼠的胃細(xì)胞，其體內(nèi)沒有出現(xiàn)腫瘤,。
研究還發(fā)現(xiàn),，利用含有癌癥基因的體細(xì)胞培育iPS，對腫瘤的發(fā)生幾率并無顯著影響,。
誘導(dǎo)多能干細(xì)胞能分化生成各種組織細(xì)胞,，同時又回避了倫理問題，被視為未來再生醫(yī)療的重要材料,。上述研究表明,，確保iPS細(xì)胞對治療的安全性，最重要的是選擇何種體細(xì)胞作為培育iPS細(xì)胞的原料,。（生物谷Bioon.com）
生物谷推薦原始出處：
Nature Biotechnology 9 July 2009 | doi:10.1038/nbt.1554
Variation in the safety of induced pluripotent stem cell lines
Kyoko Miura1,2,3,4, Yohei Okada4,5, Takashi Aoi1,3, Aki Okada1,3, Kazutoshi Takahashi1,3, Keisuke Okita1,3, Masato Nakagawa1,2,3, Michiyo Koyanagi1,3, Koji Tanabe1,2,3, Mari Ohnuki1,2,3, Daisuke Ogawa4, Eiji Ikeda6, Hideyuki Okano4 & Shinya Yamanaka1,2,3,7
We evaluated the teratoma-forming propensity of secondary neurospheres (SNS) generated from 36 mouse induced pluripotent stem (iPS) cell lines derived in 11 different ways. Teratoma-formation of SNS from embryonic fibroblast–derived iPS cells was similar to that of SNS from embryonic stem (ES) cells. In contrast, SNS from iPS cells derived from different adult tissues varied substantially in their teratoma-forming propensity, which correlated with the persistence of undifferentiated cells.
1 Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
2 Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
3 Yamanaka iPS Cell Special Project, Japan Science and Technology Agency, Kawaguchi, Japan.
4 Department of Physiology, School of Medicine, Keio University, Tokyo, Japan.
5 Kanrinmaru-Project, School of Medicine, Keio University, Tokyo, Japan.
6 Department of Pathology, School of Medicine, Keio University, Tokyo, Japan.
7 Gladstone Institute of Cardiovascular Disease, San Francisco, California, USA.
